VIVIT
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
At VIVIT in Feldkirch, Austria, clinical trials are focused on cardiovascular diseases, especially atherosclerotic cardiovascular disease, acute myocardial infarction, and broader primary prevention efforts. The research is aimed at testing new approaches that may reduce major heart-related events and improve long-term cardiovascular risk management.
- Studies in atherosclerotic cardiovascular disease and related high-risk heart conditions
- Evaluation of therapies designed to prevent major adverse cardiovascular events
- Research on lowering risk in people with elevated lipoprotein(a)
The site is contributing to trials that compare new treatment strategies with placebo or standard care to see whether they can better protect patients from serious cardiovascular complications.
Metabolic and Kidney Health Studies
Another major area of research at VIVIT involves nutritional and metabolic diseases, including obesity, overweight, and chronic kidney disease. These trials are exploring whether emerging therapies can improve both heart and kidney outcomes in people with complex metabolic risk profiles.
- Trials in obesity and overweight populations with cardiovascular risk
- Studies assessing kidney protection alongside heart outcome benefits
- Research targeting chronic kidney disease in patients with cardiometabolic disease
The overall goal is to determine whether new treatments can support healthier outcomes across interconnected conditions, rather than focusing on a single disease alone.
Risk Reduction and Biomarker-Driven Care
The trial portfolio also includes research on improving how cardiovascular risk is identified and managed, with attention to biomarker-driven care and intensified risk factor control. This work is designed to refine prevention strategies for people at high risk of recurrent events.
- Approaches to better manage residual cardiovascular risk
- Studies examining whether enhanced treatment strategies improve outcomes
- Focus on patients with elevated lipoprotein(a) and other persistent risk factors
These studies help assess whether more personalized prevention can offer stronger protection than standard guideline-based treatment alone.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Medical University Of Graz2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in VIVIT
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome | Janssen Cilag International | Phase III | Not Recruiting | Nov 2023 | Jan 2026 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Asundexian | 2 | Unknown | 2022-11-24 | 2023-01-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.